As 2025 draws to a close, we look back on another year defined by collaboration, scientific progress, and a shared global commitment to improving outcomes for people living with CML. Across continents and clinical contexts, our community came together to learn, connect, and drive forward expert care.

Strengthening Global Knowledge Through Education

Regional Discussion Groups
Our Regional Discussion Groups continued to support clinicians across Asia, Africa and Latin America. With over 750 participants, these practical, interactive, case based meetings remain one of the most valued ways clinicians from low and middle income countries (LMIC) share experience and translate expert guidance into everyday practice.

iCMLf Conversations
Our Conversations series once again brought together global experts to share insights on new research, clinical practice updates, and scientific developments from major scientific conferences. This year we were pleased to discuss biological  and clinical insights from the 66th ASH Annual Meeting, the European Heamatology Association (EHA) Congress and the ESH-iCMLf 27th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy. 

Uniting Through Global Events and Forums

ESH-iCMLf 27th Annual John Goldman Conference on CML: Biology and Therapy
This year’s ESH-iCMLf 27th Annual John Goldman Conference on CML: Biology and Therapy in Estoril brought together over 300 leading scientists and clinicians to explore new findings in CML biology and therapy. Discussions spanned leukemic stem cell science, resistance mechanisms, TKI sequencing, TFR, and future directions in personalized care.

The meeting also hosted the annual John Goldman Fun Run, with participants from around the world joining to raise funds for the work of the iCMLf and celebrate the spirit of the CML community, raising a fantastic total of $2,500.

At the Conference, our Chairman Professor Jorge Cortes gave a review of the iCMLf's year - you can view it here.

iCMLf Forum: Saudi Arabia
In November we held our first Forum in Saudi Arabia - Advancing CML Practice Through Global Collaboration. With 43 physicians in attendance and outstanding feedback, the meeting highlighted regional practice insights on; frontline TKI selection, dose optimisation, treatment free remission, almogst others

This first iCMLf Forum outside of the USA marked an important step in expanding regional engagement and strengthening our global clinical network.

iCMLf Forum: ASH

At the 67th American Society of Hematology Annual Meeting (ASH), the annual iCMLf Forum contained lively clinical discussion and scientific exchange. Topics, explored key issues including remaining contraversies from the 2025 ELN recommendations, the clinical imact of ASXL1 mutations, and progress within the iCMLf Cure Consortium.

The Foundation was also represented in the ASH scientific program through an oral abstract presentation by Professor Susan Branford, sharing results from the iCMLf/HARMONY Foundation CML Genomics project, which highlighted the prognostic impact of somatic mutations at diagnosis in chronic-phase CML.

Recognising Excellence in CML 

This year we honored exceptional leaders who have made outstanding contributions to our undersatnding and management of CML.

• Professor Satu Mustjoki (Finland) - Rowley Prize
• Dr Delphine Réa (France) -Goldman Prize
• Professor Nicholas Abinya (Kenya) - iCMLf Prize

Their dedication inspires our continued work to advance research, improve practice, and support those caring for people with CML across the world.

Honoring 25 Years of TKIs

A major highlight of 2025 was our 25 Years of TKIs campaign - marking the 25th anniversary of the therapeutic breakthrough that transformed CML from a fatal disease to a manageable condition for many. This milestone year strengthened our collective commitment to ensuring that every person with CML, everywhere, can benefit from these advances.

Driving Research Forward

Throughout 2025 we continued supporting research collaborations aimed at improving outcomes and expanding global understanding of CML.

New Clinical Trial Hub
We also launched the Clinical Trial Hub that provides regularly updated overviews of both recruiting and not-yet-recruiting trials in CML, alongside a downloadable, searchable database. It enables physicians and patients to identify potentially suitable trials more easily and supports greater global participation in CML research.

The iCMLf Genomics Alliance has made phenomenal progress with not only an abstract submitted but an oral presentation at the most prestigious international hematology conference. We have a paper published on pediatric CML in LMIC and another one submitted. Planning for the iCMLf Cure Consortium is well underway.

Looking Ahead

As we look to 2026, we are excited to build on the progress of this year with:

• Growing anticipation for the iCMLf Climb for a Cure 2026
• New series of iCMLf Conversations, case forums, and paper summaries to address emerging clinical questions
• Publications from our research alliances

Together, we will continue to push forward innovation, collaboration, and accessible education,ensuring that progress reaches every person living with CML, wherever they are.

Thank You

Every achievement this year was made possible by you, our experts and advisors leading our projects and programs along with all of our partners, donors, and community. Your commitment drives our mission and strengthens our belief that, together, we can continue improving for people with CML across the globe.

With sincere thanks,

Your iCMLf Team